Hamill John P., Senior VP, CFO, and Principal Financial and Accounting Officer at Aprea Therapeutics, Inc. ($APRE), made two open market purchases of common shares totaling about $10,900 in the last 365 days. His most recent buy occurred on January 30, 2026. These purchases rank 4,214th among 4,983 individual insiders in our database, where the average buy amounts to $1.46 million across 3.29 transactions. Hamill John P. reported no open market sales during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Warrant | 30978 | $0.00 | 30,978.0000 | 6,538,722 | 9999.99% | 0.47% |
| March 31, 2026 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Pre-Funded Warrant | 30978 | $0.81 | 30,978.0000 | 6,538,722 | 9999.99% | 0.47% |
| March 12, 2026 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | Common Stock | 10095 | $0.00 | 43,528.0000 | 6,372,938 | 30.19% | 0.16% |
| March 12, 2026 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | Stock Options (Right to Buy) | 40380 | $0.00 | 40,380.0000 | 6,372,938 | 9999.99% | 0.63% |
| Jan. 30, 2026 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Warrant | 5700 | $0.00 | 5,700.0000 | 6,372,938 | 9999.99% | 0.09% |
| Jan. 30, 2026 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Stock | 5700 | $0.89 | 33,433.0000 | 6,372,938 | 20.55% | 0.09% |
| Dec. 10, 2025 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Stock | 5000 | $1.17 | 27,733.0000 | 6,372,938 | 21.99% | 0.08% |
| Dec. 10, 2025 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Warrant | 5000 | $0.00 | 5,000.0000 | 6,372,938 | 9999.99% | 0.08% |
| March 27, 2025 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | Common Stock | 3365 | $0.00 | 22,733.0000 | 5,509,921 | 17.37% | 0.06% |
| March 27, 2025 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | Stock Options (Right to Buy) | 13460 | $0.00 | 13,460.0000 | 5,509,921 | 9999.99% | 0.24% |
| Oct. 11, 2024 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Stock | 50 | $2.46 | 19,368.0000 | 5,939,755 | 0.26% | 0.00% |
| Oct. 10, 2024 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Stock | 450 | $2.61 | 19,318.0000 | 5,939,755 | 2.38% | 0.01% |
| March 28, 2024 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | Stock Options (Right to Buy) | 13460 | $0.00 | 13,460.0000 | 3,617,607 | 9999.99% | 0.37% |
| March 28, 2024 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | Common Stock | 3365 | $0.00 | 18,868.0000 | 3,617,607 | 21.71% | 0.09% |
| March 13, 2024 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Tranche B Warrant | 505 | $0.00 | 505.0000 | 3,617,607 | 9999.99% | 0.01% |
| March 13, 2024 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Tranche A Warrant | 505 | $0.00 | 505.0000 | 3,617,607 | 9999.99% | 0.01% |
| March 13, 2024 | Aprea Therapeutics, Inc. | $APRE | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | P | Common Stock | 1010 | $7.29 | 15,503.0000 | 3,617,607 | 6.97% | 0.03% |